Clinical Trial Update: A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) [Phase 1]

View source ↗

Summary

This trial update reports the completion of a Phase 1 study of Opevesostat (MK-5684) in Chinese participants with metastatic castration-resistant prostate cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostatic Neoplasms

Drugs mentioned

• Opevesostat (MK-5684)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Status: COMPLETED